Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Duration: February 1, 2011
to
December 31, 2015
General Issues: Health Issues , Medicare/Medicaid , Pharmacy , Budget/Appropriations , Medical/Disease Research/Clinical Labs , Copyright/Patent/Trademark , Small Business
Spending: about $0 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2011: U.S. Senate,, House of Representatives, U.S. Senate, White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Bryant Hall
Legislative Director, Senator Bob Graham
Staff Director, Senate Committee on Veterans Affairs
Legislative Correspondent, Senator Bob Graham
Legislative Assistant, Senator Bob Graham
Health Care Counsel, Senator Bob Graham
Staff Director, Senate Comm. on Veterans Affairs
Staff Dir., Sen. Committee on Veterans Affairs
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2015
Tiber Creek Health Strategies, Inc. terminated an engagement in which they represented Peck Madigan Jones (On behalf of BIO) on Jan. 20, 2016.
Original Filing: 300779913.xml
3rd Quarter, 2015
In Q3, Tiber Creek Health Strategies, Inc. did no lobbying for Peck Madigan Jones (On behalf of BIO) . The report was filed on Oct. 20, 2015.
Original Filing: 300762569.xml
2nd Quarter, 2015
In Q2, Tiber Creek Health Strategies, Inc. did no lobbying for Peck Madigan Jones (On behalf of BIO) . The report was filed on July 20, 2015.
Original Filing: 300746967.xml
1st Quarter, 2015
In Q1, Tiber Creek Health Strategies, Inc. did no lobbying for Peck Madigan Jones (On behalf of BIO) . The report was filed on April 20, 2015.
Original Filing: 300727144.xml
4th Quarter, 2014
In Q4, Tiber Creek Health Strategies, Inc. did no lobbying for Peck Madigan Jones (On behalf of BIO) . The report was filed on Jan. 20, 2015.
Original Filing: 300706744.xml
3rd Quarter, 2014
In Q3, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (On behalf of BIO) . The report was filed on Oct. 20, 2014.
Original Filing: 300687915.xml
Lobbying Issues
Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Lobbying Issues
Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
2nd Quarter, 2014
In Q2, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (On behalf of BIO) . The report was filed on July 21, 2014.
Original Filing: 300668928.xml
Lobbying Issues
Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Lobbying Issues
Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
1st Quarter, 2014
In Q1, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (On behalf of BIO) . The report was filed on April 21, 2014.
Original Filing: 300646016.xml
Lobbying Issues
Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Lobbying Issues
Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (On behalf of BIO) . The report was filed on Jan. 21, 2014.
Original Filing: 300623083.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Lobbying Issues
"Track and Trace" legislation.
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Drug importation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
The sequester as it relates to FDA user fees and drug imporation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (On behalf of BIO) . The report was filed on Oct. 21, 2013.
Original Filing: 300606653.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Issues relating to the impact of the biotech industry.
Lobbying Issues
Legislation impacting patent settlements. Proposed Medicare and Medicaid cuts, including changes to Part D and Part B. "Track and Trace" legislation. Drug imporation. H.R. 3204, Drug Quality and Security Act.
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. Drug importation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
The sequester as it relates to FDA user fees and drug imporation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (On behalf of BIO) . The report was filed on July 22, 2013.
Original Filing: 300585726.xml
Lobbying Issues
340B program. Track and trace drug verification.
Lobbying Issues
Issues relating to the FDA user fee. Track and trace drug verification.
1st Quarter, 2013
In Q1, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (On behalf of BIO) . The report was filed on April 22, 2013.
Original Filing: 300563833.xml
Lobbying Issues
340B program; proposed cuts to Part B.
Lobbying Issues
Proposed cuts to Part B reimbursement.
Type of Issue
Medicare/Medicaid Pharmacy
Lobbying Issues
The sequester as it relates to FDA user fees, 340B program, Average Sales Price and drug imporation.
4th Quarter, 2012
In Q4, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (On behalf of BIO) . The report was filed on Jan. 22, 2013.
Original Filing: 300539536.xml
Lobbying Issues
340B program; proposed cuts to Part B.
Lobbying Issues
Proposed cuts to Part B reimbursement.
Lobbying Issues
Reauthroization of the Prescription Drug User Fee Act. Proposed cuts to Part B reimbursement.
3rd Quarter, 2012
In Q3, Tiber Creek Health Strategies, Inc. lobbied for Peck Madigan Jones (formely Peck, Madigan, Jones & Stewart) (On behalf of BIO) . The report was filed on Oct. 22, 2012.
Original Filing: 300521108.xml
Lobbying Issues
Issues relating to the Food and Drug Administration; 340B program; proposed cuts to Part B.
Lobbying Issues
Proposed cuts to Part B reimbursement.
Lobbying Issues
Reauthroization of the Prescription Drug User Fee Act. Proposed cuts to Part B reimbursement.
2nd Quarter, 2012
In Q2, Tiber Creek Health Strategies, Inc. lobbied for Peck, Madigan, Jones & Stewart, Inc. (On behalf of BIO) . The report was filed on July 20, 2012.
Original Filing: 300495164.xml
Lobbying Issues
Issues relating to the Food and Drug Administration. Issues related to dual eligible beneficiaries. Proposed cuts to Part B reimbursement. S. 3187, the Food and Drug Administration Safety and Innovation Act, specifically issues related to patent settlements and data exclusivity. S. AMDT. 2107, To allow the importation by individuals of safe and affordable drugs from Canada. S. AMDT. 2109, To revoke the exclusivity of certain entities that are responsible for violations of the Federal Food, Drug, and Cosmetic Act, the False Claims Act, and other certain laws. S. AMDT. 2111, To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Proposed cuts to Part B reimbursement.
Lobbying Issues
Reauthroization of the Prescription Drug User Fee Act. Proposed cuts to Part B reimbursement.
1st Quarter, 2012
In Q1, Tiber Creek Health Strategies, Inc. lobbied for Peck, Madigan, Jones & Stewart, Inc. (On behalf of BIO) . The report was filed on April 20, 2012.
Original Filing: 300474775.xml
Lobbying Issues
Reauthroization of the Prescription Drug User Fee Act. Proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
4th Quarter, 2011
In Q4, Tiber Creek Health Strategies, Inc. lobbied for Peck, Madigan, Jones & Stewart, Inc. (On behalf of BIO) . The report was filed on Jan. 20, 2012.
Original Filing: 300448420.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Qualifying Therapeutic Discovery Project tax credit. Reauthroization of the Prescription Drug User Fee Act. Proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthroization of the Prescription Drug User Fee Act. Proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
S.23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2011
In Q3, Tiber Creek Health Strategies, Inc. lobbied for Peck, Madigan, Jones & Stewart, Inc. (On behalf of BIO) . The report was filed on Oct. 20, 2011.
Original Filing: 300428480.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Qualifying Therapeutic Discovery Project tax credit. Reauthroization of the Prescription Drug User Fee Act. Proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. Proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Changes to the 340b program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthroization of the Prescription Drug User Fee Act. Proposed cuts to Part B reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
S.23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2011
In Q2, Tiber Creek Health Strategies, Inc. lobbied for Peck, Madigan, Jones & Stewart, Inc. (On behalf of BIO) . The report was filed on July 20, 2011.
Original Filing: 300404317.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Qualifying Therapeutic Discovery Project tax credit. Reauthroization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Changes to the 340b program. Qualifying Therapeutic Discovery Project tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthroization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Qualifying Therapeutic Discovery Project tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, Tiber Creek Health Strategies, Inc. lobbied for Peck, Madigan, Jones & Stewart, Inc. (On behalf of BIO) . The report was filed on April 20, 2011.
Original Filing: 300379345.xml
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D. S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Qualifying Therapeutic Discovery Project tax credit. Reauthroization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicaid Drug Rebates. Reforms to Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Changes to the 340b program. Qualifying Therapeutic Discovery Project tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthroization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Qualifying Therapeutic Discovery Project tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
Tiber Creek Health Strategies, Inc. filed a lobbying registration on March 14, 2011 to represent Peck, Madigan, Jones & Stewart, Inc. (On behalf of BIO), effective Feb. 1, 2011.
Original Filing: 300358938.xml
Issue(s) they said they’d lobby about: Health care reform; patent reform; follow-on biologics; and stem cell research. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate